Abstract:Inactivating mutations of von Hippel–Lindau (VHL) are highly prevalent in clear cell renal cell carcinoma (ccRCC). Improved understanding of the vulnerabilities of VHL-deficient ccRCC could lead to improved treatment strategies. The activity of DNA dioxygenase ten-eleven translocation (TET)2 is significantly reduced in multiple cancers by different mechanisms, but its role in ccRCC progression remains unclear. Here, we report that increased expression of TET2, but not TET1 and TET3, is negatively associated with tumor metastasis and advanced tumor stage and is positively associated with good prognosis uniquely in ccRCC among all 33 types of cancer in The Cancer Genome Atlas datasets. TET2 restrained glycolysis and pentose phosphate pathway metabolism in a VHL deficiency–dependent manner, thereby suppressing ccRCC progression. Notably, TET2 and VHL mutations tended to cooccur in ccRCC, providing genetic evidence that they cooperate to inhibit the progression of ccRCC. Mechanistically, TET2 was recruited by transcription factor HNF4α to activate FBP1 expression, which antagonized the function of hypoxia-inducible factor-1/2α (HIF1/2α) in metabolic reprogramming to impede ccRCC growth. Stimulating the TET2-FBP1 axis with vitamin C repressed the growth of VHL-deficient ccRCC with wild-type TET2 and increased the sensitivity to glycolysis inhibitors. Moreover, combined expression levels of the HNF4α–TET2-FBP1 axis served as a biomarker of prognosis in patients with ccRCC. This study reveals a unique function of TET2 in the suppression of tumor metabolism and HIF signaling, and it also provides therapeutic targets, potential drugs, and prognostic markers for the management of ccRCC. Significance: The identification of TET2-mediated inhibition of HIF signaling and tumor metabolic reprogramming provides insights for new therapeutic strategies for VHL-deficient ccRCC.

TET2 Suppresses VHL Deficiency-Driven Clear Cell Renal Cell Carcinoma by Inhibiting HIF Signaling

Supplementary Data from TET2 Suppresses VHL Deficiency-Driven Clear Cell Renal Cell Carcinoma by Inhibiting HIF Signaling

VHL suppresses autophagy and tumor growth through PHD1-dependent Beclin1 hydroxylation

Tet2 Downregulation Promotes Aml Cell Proliferation Via Pim-1 Expression

TET is targeted for proteasomal degradation by the PHD-pVHL pathway to reduce DNA hydroxymethylation

VHL Substrate Transcription Factor ZHX2 As an Oncogenic Driver in Clear Cell Renal Cell Carcinoma

TET1 Suppresses Cancer Invasion by Activating the Tissue Inhibitors of Metalloproteinases.

Tumor Suppressor TET2 Promotes Cancer Immunity and Immunotherapy Efficacy

OGT/HIF-2α Axis Promotes the Progression of Clear Cell Renal Cell Carcinoma and Regulates Its Sensitivity to Ferroptosis

Positive feedback regulation of lncRNA PVT1 and HIF2 contributes to clear cell renal cell carcinoma tumorigenesis and metastasis

TET2 is Required to Suppress Mtorc1 Signaling Through Urea Cycle with Therapeutic Potential

VHL loss enhances antitumor immunity by activating the anti-viral DNA-sensing pathway

Positive feedback regulation of lncRNA PVT1 and HIF2α contributes to clear cell renal cell carcinoma tumorigenesis and metastasis

High VHL Expression Reverses Warburg Phenotype and Enhances Immunogenicity in Kidney Tumor Cells

VHL loss reprograms the immune landscape to promote an inflammatory myeloid microenvironment in renal tumorigenesis

VHL Deficiency Augments Anthracycline Sensitivity of Clear Cell Renal Cell Carcinomas by Down-Regulating ALDH2

A Positive Feedback Loop between Inactive VHL-Triggered Histone Lactylation and PDGFRβ Signaling Drives Clear Cell Renal Cell Carcinoma Progression

Von Hippel–Lindau protein signalling in clear cell renal cell carcinoma

HIF-2α expression and metabolic signaling require ACSS2 in clear cell renal cell carcinoma

Nuclear Localization of TET2 Requires Β-Catenin Activation and Correlates with Favourable Prognosis in Colorectal Cancer

Downregulation of lncRNA APCDD1L-AS1 due to DNA hypermethylation and loss of VHL protein expression promotes the progression of clear cell renal cell carcinoma